How many drugs treat Smoking cessation assistance?

Drug Landscape tracks 7 marketed treatments for Smoking cessation assistance (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/smoking-cessation-assistance.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Smoking cessation assistance — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Smoking cessation assistance (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Smoking cessation assistance, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Chantix	varenicline	Pfizer	Cholinergic Receptor Agonist	Neuronal acetylcholine receptor; alpha4/beta2	2006-01-01
Nicorette	NICOTINE	Sanofi	Cholinergic Nicotinic Agonist [EPC]	Neuronal acetylcholine receptor; alpha4/beta2	1991-01-01
Wellbutrin	bupropion	GSK (GlaxoSmithKline)	NDRI (Norepinephrine-dopamine reuptake inhibitor)	Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor	1985-12-30
Tabex	cytisine	Pfizer		Neuronal acetylcholine receptor subunit alpha-7
Wellbutrin	Wellbutrin	Mclean Hospital		Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor
Champix	Champix	The Queen Elizabeth Hospital		Neuronal acetylcholine receptor subunit alpha-7, Neuronal acetylcholine receptor; alpha3/beta4, Neuronal acetylcholine receptor; alpha4/beta2
Elontril	Elontril	Boehringer Ingelheim		Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Smoking cessation assistance
Boehringer Ingelheim · 1 drug in Smoking cessation assistance
GSK (GlaxoSmithKline) · 1 drug in Smoking cessation assistance
Mclean Hospital · 1 drug in Smoking cessation assistance
Sanofi · 1 drug in Smoking cessation assistance
The Queen Elizabeth Hospital · 1 drug in Smoking cessation assistance

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Smoking cessation assistance:

Cite this brief

Drug Landscape (2026). Smoking cessation assistance — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/smoking-cessation-assistance. Accessed 2026-06-10.

Smoking cessation assistance full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing